7th Annual Fellows Forum in Breast Oncology - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

7th Annual Fellows Forum in Breast Oncology

Engaging the Next Generation of Oncology Leaders

Not a member of My prIME? Join now for instant access.

Explore downloadable slides on clinical cases in breast cancer discussed by the experts, presented at the 7th Annual Fellows Forum in Breast Oncology in Chicago. These case presentations provide supporting information on the reasoning behind the clinical choices made by the experts.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jun 8, 2018

Expiration Date

Jun 8, 2019

Featured Expert

  • Ana Garrido-Castro, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  • Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Case #1—Adjuvant hormonal therapy for premenopausal breast cancer

Featured Expert

  • Katherine Clifton, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
  • Debu Tripathy, MD, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Featured Topic

Case #2—Hormonal therapy for advanced premenopausal breast cancer

Featured Expert

  • Giulia Viale, MD, European Institute of Oncology, Milan, Italy
  • Giuseppe Curigliano, MD, PhD, European Institute of Oncology, University of Milan, Milan, Italy

Featured Topic

Case #3—Neoadjuvant and adjuvant treatment options for a patient with triple-negative breast cancer and a BRCA mutation

Featured Expert

  • Tomas Lyons, MB, BCh, BAO, MRCPI, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Case #4—Recurrent triple-negative breast cancer in a patient with a BRCA mutation

This educational activity is specifically designed for physicians in training in medical oncology who are interested in breast cancer.

Upon completion of this educational activity, participants should be able to:

  • Describe recent findings from ongoing clinical trials of new therapeutic options for breast cancer
  • Identify unmet needs in breast cancer research and treatment
  • Select optimal therapies for individual patients with breast cancer from among the available and emerging strategies

This educational activity is supported by a grant from Breast Cancer Research Foundation.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Burstein has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Clifton has disclosed that she has no relevant financial relationships to report. Husband has stock in WellCare (managed heatlh care plan) as part of his salary.  She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Curigliano has disclosed that he has received consulting fees from Pfizer and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Garrido-Castro has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lyons has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Norton has disclosed that he has received honoraria from ABC4; Bristol-Myers Squibb; Celgene; Context Therapeutics, LLC; Magnetar Capital LLC; NovoMedix, LLC; Pfizer; RenBio, Inc; and Samsung Bioepis Co., LTD and The Planning Shop International. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Piccart has disclosed board membership for Radius. She disclosed honoraria for speaker bureaus from AstraZeneca; Crescendo Biologics; Debiopharm; GI Therapeutics; Huya; Immunomedics; Lilly, MSD; Menarini; Novartis; Odonate; Pfizer; Periphagen; PharmaMar; and Roche-Genentech and Seattle Genetics. She received research grants from AstraZeneca; Lilly; MSD; Novartis; Pfizer; Roche-Genentech; Synthon; Servier; and Radius. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Reis-Filho has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Robson has disclosed that he has received consulting fees from AstraZeneca and McKesson. He also disclosed as an independent contractor for Abbvie, AstraZeneca, Biomarin, and Medivation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Tripathy has disclosed that he has received consulting fees from Novartis and Pfizer. He also disclosed being an independent contractor from Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Viale has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Lee Lokey, MD (medical director content reviewer/planner) –no relevant financial relationships
  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – Contracted research or research support from Amgen and Bayer.
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.